The Association of Olanzapine-Induced Metabolic Disturbance Related Measures with TCF7L2 Gene Expression
Li Ranran,Ou Jianjun,Li,Jing Zhihui,Zhao Jingping,Wu Renrong
DOI: https://doi.org/10.3760/cma.j.issn.1006-7884.2016.06.006
2016-01-01
Abstract:Objective To investigate the relationship between olanzapine induced metabolic disturbance related measures and TCF7L2 gene expression. Methods Thirty adult C57BL/6J mice, in accordance with the random number table, were divided into 3 groups that were olanzapine group (4 mg·kg-1·d-1), olanzapine (4 mg·kg-1·d-1) plus metformin (150 mg·kg-1·d-1) group and control group (saline), with 10 mice in each group. Olanzapine and olanzapine plus metformin and saline were intragastrically administered for 8 weeks. Body weight, fasting glucose and insulin, and oral glucose tolerance test (OGTT) was assessed at baseline and 8th week, homeostasis model assessment-insulin resistance (HOMA-IR), and area under of the curve of glucose(AUCg) were calculated. At the end of 8 weeks, after mice were killed by decapitation, four blood lipid items, including triglyceride, total cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) were measured, and the protein expression levels of TCF7L2 in liver, adipose and skeletal muscle tissue and mRNA and protein expression levels of TCF7L2 in pancreas were detected. Results (1) At the end of 8th week, analysis of variance and multiple comparison revealed that the levels of weight, fasting insulin, HOMA-IR, AUCg and LDL between the 3 groups were different (F=3.717-29.724,all P<0.05). Body weight, fasting insulin, HOMA-IR and LDL of mice in the olanzapine group were significantly higher compared to the placebo group (t=-2.639,-7.164,-6.238,-2.234, all P<0.05), no significant difference was found in AUCg between olanzapine group and placebo group (P>0.05);Body weight, fasting insulin, HOMA-IR, AUCg, LDL in the metformin plus olanzapine group were significantly lower than the olanzapine group (t=2.948, 6.051, 5.520, 3.874, 2.471, all P<0.05);No significant difference were found between olanzapine plus metformin group and placebo group, except AUCg, which was significant lower in the olanzapine plus metformin group compared to the placebo group (t=-2.587,P=0.015).There was no significantly difference of fasting glucose between the 3 groups (F=0.37, P=0.69). (2) At the end of 8th week, one-way ANOVA analysis showed that there was a significant difference of TCF7L2 protein expression among the 3 groups (F=20.842, 13.345, 20.149,all P<0.01). The protein expression levels of TCF7L2 in liver, skeletal muscle and adipose tissues in the olanzapine group(0.50 ± 0.08,0.46 ± 0.09,0.45 ± 0.14)were significantly higher than the placebo group (0.32±0.07,0.30±0.10,0.26±0.09;t=-5.154,-3.946,-3.874,all P<0.01),which were markedly lower in the olanzapine plus metformin group(0.30 ± 0.07,0.26 ± 0.08,0.14 ± 0.09)compared with the olanzapine group (t=5.945, 0.915, 2.418, all P<0.01). No significantly difference were founded between olanzapine plus metformin group and placebo group,except in the adipose tissue, which was significant lower compared to the placebo group (t=6.292,P=0.023). No significant differences were found between the 3 groups of TCF7L2 mRNA and protein expression level in pancreas(F=0.346, 0.102, both P>0.05). Changes of weight gain, fasting insulin, HOMA-IR and AUCg before and after drug administration were positive correlated with protein expression of TCF7L2 in liver (r=0.457,0.592,0.636, 0.460), skeletal muscle tissue (r=0.459, 0.499, 0.503, 0.399)and adipose tissues(r=0.377, 0.639, 0.584, 0.364; all P<0.05 or P<0.01). The change of HOMA-IR plays an import role in the TCF7L2 protein expression of liver, skeletal muscle (R2=0.405, 0.253;respectively), and change of fasting insulin exerts most impact on the TCF7L2 expression in adipose tissue (R2=0.408). Conclusion Olanzapine induced weight gain, insulin resistance and glucose intolerance may be correlated with the change of TCF7L2 protein expression in liver, skeletal muscle and adipose tissues.